Key result
Guideline-directed medical therapy at discharge did not reduce the risk of cardiovascular death or heart failure hospitalization in elderly and frail hospitalized patients with heart failure.
Why the study?
Post-discharge prognostic data reflecting current guideline-directed medical therapy are limited for elderly and frail hospitalized patients with heart failure.
Does guideline-directed medical therapy at discharge reduce cardiovascular death or heart failure hospitalization in elderly and frail hospitalized patients with heart failure?
Cohort (n=738)
No
Does guideline-directed medical therapy at discharge reduce cardiovascular death or heart failure hospitalization in elderly and frail hospitalized patients with heart failure?
In elderly and frail hospitalized patients with heart failure, prescription of guideline-directed medical therapy at discharge did not significantly reduce the composite of cardiovascular death or heart failure hospitalization.
Answers are grounded in this paper and cite their sources.
Should not yet change discharge GDMT prescribing in frail elderly HF; leaves open efficacy pending randomized trials.
The West Tokyo Heart Failure (WET-HF) registry has recently reported that the post-discharge prognosis for hospitalized patients with heart failure (HF) between 2011 and 2021 has been improving over time and that there has been an upward trend in the use of guideline-directed medical therapy (GDMT). However, there are few post-discharge prognostic data for elderly and frail hospitalized patients with HF. A total of 738 consecutive patients with HF hospitalized at the Konan Medical Center between April 2020 and March 2024 were retrospectively studied. The primary endpoint was cardiovascular death or HF hospitalization. The mean age and clinical frailty scale were 83.4 ± 11.0 years and 4.8 ± 2.3, respectively. The average prescription rates of GDMT at discharge over the 4-year period were 71.0% for beta-blockers, 23.4% for angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), 42.7% for angiotensin receptor neprilysin inhibitor (ARNI), 56.1% for mineralocorticoid receptor antagonists (MRA), and 23.2% for sodium-glucose cotransporter 2 (SGLT2) inhibitors. Although, there has been an upward trend in the use of GDMT, the Kaplan-Meier curve showed no improvement in prognosis over time. Multivariate analyses showed that none of the beta-blockers, ACE-I, ARB, ARNI, MRA, or SGLT2-inhibitors at discharge reduced the primary endpoint for hospitalized patients with HF. GDMT alone may not be sufficient to improve the prognosis of elderly and frail hospitalized patients with HF. In addition to GDMT, comprehensive management by a multidisciplinary team may be vital, since currently there seems to be no one-size-fits-all approach for these patients.
No takes yet. Share an insight, caveat, or question.
Odajima et al. (2025) conducted a cohort in Heart failure (n=738). Guideline-directed medical therapy (GDMT) vs. No GDMT was evaluated on Cardiovascular death or heart failure hospitalization. Guideline-directed medical therapy at discharge did not reduce the risk of cardiovascular death or heart failure hospitalization in elderly and frail hospitalized patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: